Cite
Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients.
MLA
Gane, E., et al. “Efficacy of 12 or 18 Weeks of Elbasvir plus Grazoprevir with Ribavirin in Treatment-Naïve, Noncirrhotic HCV Genotype 3-Infected Patients.” Journal of Viral Hepatitis, vol. 24, no. 10, Oct. 2017, pp. 895–99. EBSCOhost, https://doi.org/10.1111/jvh.12719.
APA
Gane, E., Nahass, R., Luketic, V., Asante-Appiah, E., Hwang, P., Robertson, M., Wahl, J., Barr, E., & Haber, B. (2017). Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients. Journal of Viral Hepatitis, 24(10), 895–899. https://doi.org/10.1111/jvh.12719
Chicago
Gane, E, R Nahass, V Luketic, E Asante-Appiah, P Hwang, M Robertson, J Wahl, E Barr, and B Haber. 2017. “Efficacy of 12 or 18 Weeks of Elbasvir plus Grazoprevir with Ribavirin in Treatment-Naïve, Noncirrhotic HCV Genotype 3-Infected Patients.” Journal of Viral Hepatitis 24 (10): 895–99. doi:10.1111/jvh.12719.